> top > projects > Inflammaging > docs > PubMed:25314077 > annotations
Inflammaging  

PubMed:25314077 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-86 Sentence denotes Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
T1 0-86 Sentence denotes Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
T2 87-251 Sentence denotes Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity.
T2 87-251 Sentence denotes Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity.
T3 252-397 Sentence denotes Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM.
T3 252-397 Sentence denotes Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM.
T4 398-584 Sentence denotes Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells.
T4 398-584 Sentence denotes Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells.
T5 585-722 Sentence denotes DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro.
T5 585-722 Sentence denotes DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro.
T6 723-825 Sentence denotes Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses.
T6 723-825 Sentence denotes Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses.
T7 826-957 Sentence denotes Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit.
T7 826-957 Sentence denotes Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit.